Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study

Antiviral Therapy

Volumn 12, Issue 8, 2007, Pages 1165-1173

  Fux, Christoph A ^a   Simcock, Mathew ^b,c   Wolbers, Marcel ^b   Bucher, Heiner C ^b,c   Hirschel, Bernard ^d   Opravil, Milos ^e   Vernazza, Pietro ^f   Cavassini, Matthias ^g   Bernasconi, Enos ^h   Elzi, Luigia ^c   Furrer, Hansjakob ^a   Battegay, M ^k   Bernasconi, E ^k   Boni J ^k   Bucher, H ^k   Burgisser Ph ^k   Cattacin, S ^k   Cavassini, M ^k   Dubs, R ^k   Egger, M ^k   Elzi, L ^k   Erb, P ^k   Fischer, M ^k   Flepp, M ^k   Fontana, A ^k   Francioli, P ^g   Furrer, H ⁱ   Fux, C ^k   Gorgievski, M ^k   Gunthard H ^k   Hirschel, B ^k   Hosli I ^k   Kahlert, Ch ^k   Kaiser, L ^k   Karrer, U ^k   Keiser, O ^k   Kind, C ^k   Klimkait, Th ^k   Ledergerber, B ^k   Martinez, B ^k   Muller N ^k   Nadal, D ^k   Opravil, M ^k   Paccaud, F ^k   Pantaleo, G ^k   Perrin, L ^k   Piffaretti, J C ^k   Rauch, A ^k   Rickenbach, M ^j   Rudin, C ^k   Schmid, P ^k   Schultze, D ^k   Schupbach J ^k   Speck, R ^k   Taffe P ^k   Tarr, P ^k   Telenti, A ^k   Trkola, A ^k   Vernazza, P ^k   Weber, R ^k   Yerly, S ^k   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h Hospital of Lugano   (Switzerland)

ⁱ Clinical and Laboratory Committee

^j Data Centre

^k Data Centre ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; TENOFOVIR;

ADULT; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY; MALE; PHOSPHONIC ACIDS; SWITZERLAND;

EID: 38049091036     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
2. Schooley RT, Ruane P, Myers RA, et al. Tenofovir Df in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. Aids 2002; 16:1257-1263.
3. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
4. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-1333.
5. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37:e174-176.
6. Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:e41-43.
7. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
8. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
9. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 2005; 19:2031-2033.
10. Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29:948-949.
11. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
12. th Conference on Retroviruses & Opportunistic Infections. 5-8 February 2006, Denver, USA. Abstract 779.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
15. Staehelin C, Rickenbach M, Low N, et al. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17:2237-2244.
16. Julg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS 2005; 19:1332-1333.
17. El Sahly HM, Teeter L, Zerai T, et al. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS 2006; 20:786-787.
18. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93-95.
19. Jaber BL, Madias NE. Progression of chronic kidney disease: can it be prevented or arrested? Am J Med 2005; 118:1323-1330.
20. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004; 37:1489-1495.
21. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
22. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
23. Squires K, Pozniak AL, Pierone G, Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-320.
24. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18:1074-1076.
25. Gayet-Ageron A, Ananworanich J, Jupimai T, et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 2007; 59:1034-1037.
26. Shikuma CM, Zackin R, Sattler F, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1223-1230.
27. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 2005; 19:421-424.
28. Gerard L, Chazallon C, Taburet AM, et al. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir Ther 2007; 12:31-39.
29. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194:1481-1491.
30. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297-3304.
31. Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11:79-86.
32. Black R. Rose & Black's Clinical Problems in Nephrology. Boston: Little, Brown and Company; 1996.
33. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
34. Opravil M, Keusch G, Luthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother 1993; 37:1056-1060.
35. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36:29-34.
36. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049-2060.